Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: a randomised, double-blind, placebo-controlled, phase 2 trial
- 5 May 2016
- journal article
- research article
- Published by Elsevier BV in The Lancet Respiratory Medicine
- Vol. 4 (6), 445-453
- https://doi.org/10.1016/s2213-2600(16)30044-3
Abstract
No abstract availableKeywords
Funding Information
- National Institute for Health and Care Research
- Imperial College London
- Roche
- Royal Brompton and Harefield NHS Foundation Trust
This publication has 19 references indexed in Scilit:
- Prednisone, Azathioprine, andN-Acetylcysteine for Pulmonary FibrosisThe New England Journal of Medicine, 2012
- Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trialsThe Lancet, 2011
- Six-Minute-Walk Test in Idiopathic Pulmonary FibrosisAmerican Journal of Respiratory and Critical Care Medicine, 2011
- An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and ManagementAmerican Journal of Respiratory and Critical Care Medicine, 2011
- Clinical Course and Prediction of Survival in Idiopathic Pulmonary FibrosisAmerican Journal of Respiratory and Critical Care Medicine, 2011
- A Comprehensive Review of the Adverse Effects of Systemic CorticosteroidsOtolaryngologic Clinics of North America, 2010
- Lung function in idiopathic pulmonary fibrosis - extended analyses of the IFIGENIA trialRespiratory Research, 2009
- Idiopathic pulmonary fibrosisOrphanet Journal of Rare Diseases, 2008
- Classification and Natural History of the Idiopathic Interstitial PneumoniasProceedings of the American Thoracic Society, 2006
- High-Dose Acetylcysteine in Idiopathic Pulmonary FibrosisThe New England Journal of Medicine, 2005